CANGET BIOTEKPHARMA, LLC
BUFFALO, NY · CIK 0001781984 · Biotech · Private
FL118, a small molecule therapeutic targeting DDX5 oncogenic protein for pancreatic cancer treatment
- Grants
- $2.7M
- 5 awards
- Sector median: 1
- Raised
- $25K
- 1 Form D · Jul 2019
- 87 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 3 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer | $903,055 | |
| Federal grant | Department of Health and Human Services · Phase II · A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer | $988,326 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma | $224,919 | |
| Federal grant | Department of Health and Human Services · Phase II · A small molecule broad spectrum inhibitor of antiapoptotic genes to treat cancer | $210,000 | |
| Private capital raised | Form D · SEC | $25,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials | $400,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1233 | Artemis Biosystems, Inc. | — | $50K |
| 1234 | Factor Medical, LLC | — | $50K |
| 1235 | Auvi Labs, Inc. | — | $543K |
| 1236 | CANGET BIOTEKPHARMA, LLC | — | $25K |
| 1237 | AIRNA | — | $1K |
| 1238 | SCALMIBIO, INC | — | — |
| 1239 | Tessera Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Fengzhi LiDirector · Executive Officer
- Geoffrey WhiteExecutive Officer
Patents
- Novel Anticancer Drug FL118 Formulation For Treatment Of Human Cancergranted
- Matter Of Composition, Synthesis, Formulation And Application Of Fl 118 Platform Positions 7 And 9-DERIVED Analogues For Treatment Of Human Diseaseapplication
- Matter Of Composition, Synthesis, Formulation And Application Of FL118 Platform Positions 7 And 9-DERIVED Analogues For Treatment Of Human Diseasegranted
- Use Of The FL118 Core Chemical Structure Platform To Generate FL118 Derivatives For Treatment Of Human Diseasegranted
- Novel Anticancer Drug FL118 Formulation In Combination With Immunotherapy For Treatment Of Human Cancerapplication
- FL118 Complexes For Targeting DDX5, UBE2T Or USP2Aapplication
- Use Of The FL118 Core Chemical Structure Platform To Generate FL118 Derivatives For Treatment Of Human Diseaseapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.